James E. Bradner

54.1k total citations · 18 hit papers
217 papers, 28.8k citations indexed

About

James E. Bradner is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, James E. Bradner has authored 217 papers receiving a total of 28.8k indexed citations (citations by other indexed papers that have themselves been cited), including 201 papers in Molecular Biology, 58 papers in Hematology and 41 papers in Oncology. Recurrent topics in James E. Bradner's work include Protein Degradation and Inhibitors (142 papers), Ubiquitin and proteasome pathways (66 papers) and Histone Deacetylase Inhibitors Research (65 papers). James E. Bradner is often cited by papers focused on Protein Degradation and Inhibitors (142 papers), Ubiquitin and proteasome pathways (66 papers) and Histone Deacetylase Inhibitors Research (65 papers). James E. Bradner collaborates with scholars based in United States, China and United Kingdom. James E. Bradner's co-authors include Richard A. Young, Jun Qi, Dennis L. Buckley, Denes Hnisz, Joshiawa Paulk, Justin M. Roberts, Ralph Mazitschek, Charles Y. Lin, Tong Ihn Lee and Sirano Dhe‐Paganon and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

James E. Bradner

212 papers receiving 28.4k citations

Hit Papers

RNAi screen identifies Brd4 as a therapeutic target in ac... 2007 2026 2013 2019 2011 2009 2015 2012 2013 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
    2011 1.4k citations Jun Qi, James E. Bradner et al. profile →
  2. HDAC2 negatively regulates memory formation and synaptic plasticity
    2009 1.3k citations Ralph Mazitschek, James E. Bradner et al. profile →
  3. Phthalimide conjugation as a strategy for in vivo target protein degradation
    2015 1.3k citations Georg E. Winter, Dennis L. Buckley et al. Science profile →
  4. Transcriptional Amplification in Tumor Cells with Elevated c-Myc
    2012 1.1k citations James E. Bradner, Tong Ihn Lee et al. profile →
  5. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
    2013 1.1k citations Gang Lu, Richard E. Middleton et al. Science profile →
  6. Transcriptional Addiction in Cancer
    2017 756 citations James E. Bradner, Richard A. Young et al. profile →
  7. Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies
    2007 699 citations Jayne M. Stommel, Alec C. Kimmelman et al. Science profile →
  8. YY1 Is a Structural Regulator of Enhancer-Promoter Loops
    2017 661 citations Brian J. Abraham, Dennis L. Buckley et al. profile →
  9. The dTAG system for immediate and target-specific protein degradation
    2018 652 citations Justin M. Roberts, Dennis L. Buckley et al. profile →
  10. Direct inhibition of the NOTCH transcription factor complex
    2009 619 citations Tina Davis, Andrew L. Kung et al. profile →
  11. PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
    2007 598 citations Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Cancer Research profile →
  12. Chemical phylogenetics of histone deacetylases
    2010 581 citations James E. Bradner, Ralph Mazitschek et al. profile →
  13. Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
    2013 550 citations Jun Qi, Andrew L. Kung et al. profile →
  14. Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
    2013 457 citations Alexandre Puissant, Stacey M. Frumm et al. Cancer Discovery profile →
  15. NF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis
    2014 453 citations Andrew L. Kung, James E. Bradner et al. profile →
  16. Plasticity in binding confers selectivity in ligand-induced protein degradation
    2018 427 citations Dennis L. Buckley, James E. Bradner et al. profile →
  17. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
    2017 402 citations Richard A. Young, James E. Bradner et al. profile →
  18. A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
    2017 330 citations Joshiawa Paulk, Dennis L. Buckley et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James E. Bradner United States 86 24.1k 6.3k 5.8k 2.3k 1.8k 217 28.8k
Steven Grant United States 79 16.7k 0.7× 6.3k 1.0× 3.6k 0.6× 2.3k 1.0× 2.2k 1.2× 451 23.2k
Andrew L. Kung United States 81 16.6k 0.7× 6.6k 1.0× 4.1k 0.7× 4.6k 2.0× 2.9k 1.6× 285 24.2k
Victoria M. Richon United States 68 20.3k 0.8× 5.2k 0.8× 2.6k 0.5× 1.4k 0.6× 1.4k 0.8× 123 23.0k
Craig M. Crews United States 90 27.8k 1.2× 11.2k 1.8× 5.6k 1.0× 1.5k 0.7× 1.3k 0.7× 209 32.0k
Ricky W. Johnstone Australia 77 18.7k 0.8× 7.8k 1.2× 2.0k 0.3× 2.2k 0.9× 5.3k 2.9× 248 25.4k
Nathanael S. Gray United States 104 30.5k 1.3× 10.9k 1.7× 3.4k 0.6× 3.0k 1.3× 3.2k 1.8× 476 42.2k
E. Premkumar Reddy United States 63 10.4k 0.4× 4.8k 0.8× 1.5k 0.2× 2.1k 0.9× 2.7k 1.5× 203 17.2k
Hong Wu United States 89 16.6k 0.7× 7.2k 1.1× 2.6k 0.5× 4.5k 2.0× 3.1k 1.7× 204 26.2k
Kevan M. Shokat United States 96 24.3k 1.0× 6.9k 1.1× 1.1k 0.2× 2.4k 1.0× 4.0k 2.2× 305 34.2k
Shoukat Dedhar Canada 92 15.8k 0.7× 5.1k 0.8× 971 0.2× 4.1k 1.8× 3.2k 1.7× 260 26.4k

Countries citing papers authored by James E. Bradner

Since Specialization
Citations

This map shows the geographic impact of James E. Bradner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Bradner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Bradner more than expected).

Fields of papers citing papers by James E. Bradner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James E. Bradner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Bradner. The network helps show where James E. Bradner may publish in the future.

Co-authorship network of co-authors of James E. Bradner

This figure shows the co-authorship network connecting the top 25 collaborators of James E. Bradner. A scholar is included among the top collaborators of James E. Bradner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James E. Bradner. James E. Bradner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Miller, Aubrey L., Patrick L. Garcia, Robert C.A.M. van Waardenburg, et al.. (2019). The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors. EBioMedicine. 44. 419–430. 84 indexed citations
2.
Hemming, Matthew L., Matthew A. Lawlor, Rhamy Zeid, et al.. (2018). Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proceedings of the National Academy of Sciences. 115(25). E5746–E5755. 26 indexed citations
3.
Hogg, Simon J., Andrea Newbold, Stephin J. Vervoort, et al.. (2016). BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. Molecular Cancer Therapeutics. 15(9). 2030–2041. 50 indexed citations
4.
Shahbazi, Jeyran, Bernard Atmadibrata, James E. Bradner, et al.. (2016). The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Clinical Cancer Research. 22(10). 2534–2544. 101 indexed citations
5.
Kühn, Michael W.M., E Song, Zhaohui Feng, et al.. (2016). Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. Cancer Discovery. 6(10). 1166–1181. 166 indexed citations
6.
Winter, Georg E., Dennis L. Buckley, Joshiawa Paulk, et al.. (2015). Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 348(6241). 1376–1381. 1253 indexed citations breakdown →
7.
Xiong, Ji, Daniel Benjamin Dadon, Brian J. Abraham, et al.. (2015). Chromatin proteomic profiling reveals novel proteins associated with histone-marked genomic regions. Proceedings of the National Academy of Sciences. 112(12). 3841–3846. 110 indexed citations
8.
Stubbs, Matthew C., Won-Il Kim, Tina Davis, et al.. (2015). Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clinical Cancer Research. 21(10). 2348–2358. 59 indexed citations
9.
Wang, Ranran, Wei Liu, James E. Bradner, et al.. (2014). Activation of SOX2 Expression by BRD4-NUT Oncogenic Fusion Drives Neoplastic Transformation in NUT Midline Carcinoma. Cancer Research. 74(12). 3332–3343. 45 indexed citations
10.
Cho, Hyejin, Tali Herzka, Zheng Wu, et al.. (2014). RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of Pten -Mutant Metastasis. Cancer Discovery. 4(3). 318–333. 68 indexed citations
11.
Schubbert, Suzanne, et al.. (2014). Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia. Cancer Research. 74(23). 7048–7059. 38 indexed citations
12.
Fiskus, Warren, Sunil Sharma, Jun Qi, et al.. (2014). Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells. Molecular Cancer Therapeutics. 13(5). 1142–1154. 155 indexed citations
13.
Trabucco, Sally E., Rachel M. Gerstein, Andrew M. Evens, et al.. (2014). Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma. Clinical Cancer Research. 21(1). 113–122. 116 indexed citations
14.
Puissant, Alexandre, Stacey M. Frumm, Gabriela Alexe, et al.. (2013). Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer Discovery. 3(3). 308–323. 457 indexed citations breakdown →
15.
Lu, Gang, Richard E. Middleton, Huahang Sun, et al.. (2013). The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins. Science. 343(6168). 305–309. 1108 indexed citations breakdown →
16.
Archin, Nancie M., Anna C. Belkina, Gerald V. Denis, et al.. (2012). BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. Journal of Leukocyte Biology. 92(6). 1147–1154. 210 indexed citations
17.
Lockwood, William W., Kreshnik Zejnullahu, James E. Bradner, & Harold Varmus. (2012). Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proceedings of the National Academy of Sciences. 109(47). 19408–19413. 277 indexed citations
18.
Bazzaro, Martina, Zhenhua Lin, Antonio Santillan, et al.. (2008). Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC6 Inhibitor. Clinical Cancer Research. 14(22). 7340–7347. 107 indexed citations
19.
Engelman, Jeffrey A., Kreshnik Zejnullahu, Eugene Lifshits, et al.. (2007). PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib. Cancer Research. 67(24). 11924–11932. 598 indexed citations breakdown →
20.
Stommel, Jayne M., Alec C. Kimmelman, Haoqiang Ying, et al.. (2007). Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies. Science. 318(5848). 287–290. 699 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven Grant Breakdown of academic impact, for papers by Andrew L. Kung Breakdown of academic impact, for papers by Victoria M. Richon Breakdown of academic impact, for papers by Craig M. Crews Breakdown of academic impact, for papers by Ricky W. Johnstone Breakdown of academic impact, for papers by Nathanael S. Gray Breakdown of academic impact, for papers by E. Premkumar Reddy Breakdown of academic impact, for papers by Hong Wu Breakdown of academic impact, for papers by Kevan M. Shokat Breakdown of academic impact, for papers by Shoukat Dedhar
Rankless by CCL
2026